GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GI Innovation Inc (XKRX:358570) » Definitions » Institutional Ownership

GI Innovation (XKRX:358570) Institutional Ownership : 4.91% (As of Apr. 13, 2025)


View and export this data going back to 2023. Start your Free Trial

What is GI Innovation Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, GI Innovation's institutional ownership is 4.91%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, GI Innovation's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, GI Innovation's Float Percentage Of Total Shares Outstanding is 0.00%.


GI Innovation Institutional Ownership Historical Data

The historical data trend for GI Innovation's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GI Innovation Institutional Ownership Chart

GI Innovation Historical Data

The historical data trend for GI Innovation can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 6.45 5.12 5.98 7.29 7.75 8.07 6.26 5.77 5.77 4.91

GI Innovation Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


GI Innovation Business Description

Traded in Other Exchanges
N/A
Address
Songpa-daero 167, Room 1116 of A-dong, Songpa-gu, Seoul, KOR, 05855
GI Innovation Inc is a bio-venture company that researches and develops protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and developing a fusion protein using the GI-SMART platform.

GI Innovation Headlines

No Headlines